Assays

Things Are Not Well at Nanosphere (NSPH)

In September of 2013, we highlighted Nanosphere (NASDAQ:NSPH) and their promises of high margins for a technology which uses gold nanoparticles to develop clinical diagnostic tests that are two to three times as sensitive as those commonly used in hospital today. Based on the discoveries of Chad Mirkin, Nanosphere’s benchtop Verigene System allows for simple, low cost, […]

MDxHealth Improves Prostate Cancer Biopsies

According to the Prostate Cancer Foundation, prostate cancer is the most common non-skin cancer in America, affecting 1 in 6 men. One new case occurs every 2.3 minutes and a man dies from prostate cancer every 16 minutes. It is estimated that there are more than 2.5 million American men currently living with prostate cancer. One of the […]

Molecular Food Testing Company Roka Bioscience to IPO

According to the Centers for Disease Control, every year 48 million people in the U.S.A get sick from foodborne illnesses. Of these, 128,000 are hospitalized, and 3,000 will ultimately die from it. In January 2011, President Obama signed the Food Safety Modernization Act into law. This piece of legislation was the most sweeping reform of food […]

Cash Burning Nanosphere Promises High Margins

When the use of the word “nano” became an attractive addition to a company’s name in 2004, many companies chose to capitalize on this. The word “Nano” started to crop up everywhere, mostly in over-the-counter (OTC) company names and products, few of which survived almost ten years later. One company that had an IPO in […]

nanoString’s lackluster IPO

One of the companies posted by a user in the Nanalyze forums in 2003 was Illlumina (NASDAQ:ILMN), a company involved in genetic analysis solutions. If you had invested $1000 in Illumina at the time of this user’s post, you would have $42,220 today. While most people have heard the term nanotechnology, fewer people are familiar […]